Cyclo Therapeutics Performance
| CYTHDelisted Stock | USD 0.72 0.06 9.09% |
The firm shows a Beta (market volatility) of 1.49, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cyclo Therapeutics will likely underperform. Cyclo Therapeutics right now shows a risk of 0.0%. Please confirm Cyclo Therapeutics standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to decide if Cyclo Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Cyclo Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Cyclo Therapeutics is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 1.5 M | |
| Free Cash Flow | -16.2 M |
Cyclo |
Cyclo Therapeutics Relative Risk vs. Return Landscape
If you would invest 72.00 in Cyclo Therapeutics on April 25, 2025 and sell it today you would earn a total of 0.00 from holding Cyclo Therapeutics or generate 0.0% return on investment over 90 days. Cyclo Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Cyclo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cyclo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyclo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cyclo Therapeutics, and traders can use it to determine the average amount a Cyclo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CYTH |
Based on monthly moving average Cyclo Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclo Therapeutics by adding Cyclo Therapeutics to a well-diversified portfolio.
Cyclo Therapeutics Fundamentals Growth
Cyclo Stock prices reflect investors' perceptions of the future prospects and financial health of Cyclo Therapeutics, and Cyclo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyclo Stock performance.
| Return On Equity | -226.64 | |||
| Return On Asset | -2.84 | |||
| Operating Margin | (35.46) % | |||
| Current Valuation | 34.87 M | |||
| Shares Outstanding | 32.74 M | |||
| Price To Book | 59.10 X | |||
| Price To Sales | 27.09 X | |||
| Revenue | 1.08 M | |||
| EBITDA | (20.03 M) | |||
| Cash And Equivalents | 4.29 M | |||
| Cash Per Share | 0.51 X | |||
| Total Debt | 1.03 M | |||
| Book Value Per Share | (0.47) X | |||
| Cash Flow From Operations | (16.19 M) | |||
| Earnings Per Share | (0.90) X | |||
| Total Asset | 13.25 M | |||
| Retained Earnings | (83.86 M) | |||
About Cyclo Therapeutics Performance
By evaluating Cyclo Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Cyclo Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cyclo Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cyclo Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida. Cyclo Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Things to note about Cyclo Therapeutics performance evaluation
Checking the ongoing alerts about Cyclo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cyclo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyclo Therapeutics is not yet fully synchronised with the market data | |
| Cyclo Therapeutics has some characteristics of a very speculative penny stock | |
| Cyclo Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.08 M. Net Loss for the year was (20.06 M) with profit before overhead, payroll, taxes, and interest of 794.48 K. | |
| Cyclo Therapeutics currently holds about 4.29 M in cash with (16.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| Roughly 48.0% of the company shares are held by company insiders |
- Analyzing Cyclo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyclo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cyclo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyclo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyclo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyclo Therapeutics' stock. These opinions can provide insight into Cyclo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Cyclo Stock
If you are still planning to invest in Cyclo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyclo Therapeutics' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |